Skip to content
OpenCapital
Get started

Replimune Group REPL Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
——
Immunovant, Inc. logo
Immunovant, Inc.IMVT
——

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?
Replimune Group (REPL) reported share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value of $8.28M in Q4 2025.
How has Replimune Group's share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value changed year-over-year?
Replimune Group's share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value decreased by 30.9% year-over-year, from $11.98M to $8.28M.